Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.61 |
| ▸ | DHFR | P00374 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levofacetoperane SCHEMBL49158 | 0.86 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Levofacetoperane SCHEMBL15003778 | 0.86 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Levofacetoperane SCHEMBL1651100 | 0.86 | SLC6A3 (0.64) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL16437808 | 0.82 | SLC6A3 (0.46) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL27995473 | 0.80 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL18636884 | 0.79 | SLC6A3 (0.57) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL16000085 | 0.79 | IDO1 (0.55) | SLC6A3SLC6A2SLC6A4LMNATSHR | |
| SCHEMBL27884792 | 0.79 | SLC6A3 (0.51) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL12543306 | 0.79 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL15705102 | 0.79 | SLC6A3 (0.59) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3412663-B1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2022-09-07 | — | — | EP | disclosed |
| EP-3330256-B1 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2021-06-16 | — | — | EP | disclosed |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2021-05-18 | — | — | US | disclosed |
| US-20200087302-A1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-2952503-B1 | CARBOXYLIC ACID DERIVATIVES AS HIV REPLICATION INHIBITOR | SHIONOGI & CO (JP) | 2019-10-23 | — | — | EP | disclosed |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SHIONOGI & CO., LTD. (JP) | 2018-07-05 | — | — | US | disclosed |
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3330256-A1 | HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY | Shionogi & Co., Ltd. (JP) | 2018-06-06 | — | — | EP | disclosed |
| US-9975906-B2 | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | SHIONOGI & CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-03-16 | — | — | US | disclosed |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO (JP) | 2017-03-09 | — | — | US | disclosed |
| US-9499533-B2 | Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity | SHIONOGI & CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162876-A1 | NITROGEN-CONTAINING TRICYCLIC DERIVATIVES HAVING HIV REPLICATION INHIBITORY ACTIVITY | NR4A3, CCR3, NCOA3 | SLC6A3 400/4885SLC6A2 1387/4885SLC6A4 1326/4885 |
| US-20170066759-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | SLC6A3 495/4885SLC6A2 325/4885SLC6A4 99/4885 |
| US-20170073337-A1 | DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY | BACE1, BACE2, APP | SLC6A3 388/4885SLC6A2 443/4885SLC6A4 1555/4885 |
| US-20170253607-A1 | LONG-ACTING HIV PROTEASE INHIBITOR | CPN1, HAT1, PRSS1 | SLC6A3 1248/4885SLC6A2 1784/4885SLC6A4 944/4885 |
| US-20200087302-A1 | NITROGEN-CONTAINING HETEROCYCLE AND CARBOCYCLE DERIVATIVES HAVING TRKA INHIBITORY ACTIVITY | NTRK2, NTRK3, NTRK1 | SLC6A3 180/4885SLC6A2 299/4885SLC6A4 134/4885 |
| US-20180186814-A1 | TRICYCLIC COMPOUND HAVING SULFINYL OR SULFONYL | SULT1E1, ABCC5, ABCC4 | SLC6A3 201/4885SLC6A2 1091/4885SLC6A4 103/4885 |
| US-20150038483-A1 | AROMATIC 5-MEMBERED HETEROCYCLIC DERIVATIVE HAVING TRPV4-INHIBITING ACTIVITY | TRPV4, TRPC4, TRPV2 | SLC6A3 495/4885SLC6A2 325/4885SLC6A4 99/4885 |
| US-11008320-B2 | Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity | NTRK2, NTRK3, NTRK1 | SLC6A3 180/4885SLC6A2 299/4885SLC6A4 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.